NHS gene testing does not detect half of people at cancer risk 21 Feb 2022 NHS guidelines for gene testing miss half of people carrying inherited genetic changes linked to cancer, a new study reports. Find out more Show/Hide
NICE misses golden opportunity to enhance access to innovative cancer drugs 07 Feb 2022 Cancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity to ensure its evaluation methods support approval of the most innovative, potentially game-changing drugs. Find out more Show/Hide
The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer 15 Jul 2021 The Institute of Cancer Research, London, is disappointed at the decision by NICE not to recommend abiraterone as a first-line NHS treatment for newly diagnosed, advanced prostate cancer. Find out more Show/Hide
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer 29 Oct 2020
ICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’ 07 Sep 2020
Approval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’ 06 May 2020
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
The ICR responds to approval of abiraterone as first-line treatment for advanced prostate cancer on the NHS in Scotland 13 Jan 2020